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Abstract
Background: Early life exposure to tobacco smoke has been extensively studied but the role of second-hand
smoke (SHS) for new-onset respiratory symptoms and lung function decline in adulthood has not been widely
investigated in longitudinal studies. Our aim is to investigate the associations of exposure to SHS in adults with
respiratory symptoms, respiratory conditions and lung function over 20 years.
Methods: We used information from 3011 adults from 26 centres in 12 countries who participated in the European
Community Respiratory Health Surveys I-III and were never or former smokers at all three surveys. Associations of
SHS exposure with respiratory health (asthma symptom score, asthma, chronic bronchitis, COPD) were analysed
using generalised linear mixed-effects models adjusted for confounding factors (including sex, age, smoking status,
socioeconomic status and allergic sensitisation). Linear mixed-effects models with additional adjustment for height
were used to assess the relationships between SHS exposure and lung function levels and decline.
Results: Reported exposure to SHS decreased in all 26 study centres over time. The prevalence of SHS exposure
was 38.7% at baseline (1990–1994) and 7.1% after the 20-year follow-up (2008–2011). On average 2.4% of the study
participants were not exposed at the first, but were exposed at the third examination. An increase in SHS exposure over
time was associated with doctor-diagnosed asthma (odds ratio (OR): 2.7; 95% confidence interval (95%-CI): 1.2–5.9),
chronic bronchitis (OR: 4.8; 95%-CI: 1.6–15.0), asthma symptom score (count ratio (CR): 1.9; 95%-CI: 1.2–2.9) and dyspnoea
(OR: 2.7; 95%-CI: 1.1–6.7) compared to never exposed to SHS. Associations between increase in SHS exposure and
incidence of COPD (OR: 2.0; 95%-CI: 0.6–6.0) or lung function (β: − 49ml; 95%-CI: -132, 35 for FEV1 and β: − 62ml;
95%-CI: -165, 40 for FVC) were not apparent.
Conclusion: Exposure to second-hand smoke may lead to respiratory symptoms, but this is not accompanied by lung
function changes.
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Introduction
Exposure to second-hand smoke remains one of the
most common indoor pollutants worldwide. In an over-
view paper from 2011 as many as 40% of children, 35%
of women, and 33% of men were regularly exposed to
second-hand smoke indoors worldwide [1]. Children
exposed to passive smoke have deficits in lung growth
[2–5]. However, the effect of environmental tobacco
smoke on respiratory disorders and lung function has
not been widely investigated and the associations are less
clear in adults [6–8].
Emerging evidence indicates that exposure to second-
hand smoke is related to the development of chronic ob-
structive pulmonary disease (COPD). Based on three
studies [8–10], a meta-analysis [11] found an increased
relative risk (RR = 1.7, 95% CI: 1.4–2.0) of COPD defined
by spirometry in people exposed to passive smoking. A
link between exposure to second-hand smoke and an ac-
celerated loss of lung function [6, 8] was suggested, but
the evidence is not strong. Results from cross-sectional
analyses of data from middle aged adults participating in
the European Community Respiratory Health Survey
(ECRHS) showed adverse effects of passive smoking on
respiratory symptoms including increased bronchial re-
sponsiveness, but the negative association with lung
function was not statistically significant [12]. In addition,
a variety of early life factors including maternal smoking
during pregnancy showed an association with asthma
and poor lung function in adulthood [13, 14]. A recent
report on life-long exposure to tobacco smoke and lung
function trajectories to middle age reported accelerated
lung function decline in the exposed subjects [15]. How-
ever, some research [16, 17] indicates that current or
former smokers often suffer from respiratory symptoms,
although lung function is still within normal range and
the criteria for COPD assessed by spirometry are not
met. While there is mounting evidence that second-hand
smoke exposure causes respiratory symptoms and lung
function deficits at younger ages including young adult-
hood, the impact in older age groups is less clear.
We aimed to analyse the association of exposure to
second-hand smoke with respiratory diseases such as
asthma, bronchitis and COPD, asthma-related symptoms
and spirometric pulmonary function in long-term follow
ups of young and middle aged adults within a large
European multicentre study (ECRHS).
Methods
Study population
The European Community Respiratory Health Survey
(ECRHS) is a multicentre population-based cohort study
that began in 1990–1994. Fifty-six centres across Europe
and other parts of the world from 25 countries took
part. Young adults aged between 20 and 44 years were
selected at random from available population-based reg-
isters to take part in the survey. It was a two-stage study,
with around 200,000 participants in the questionnaire
stage 1, and 26,000 in the clinical stage 2. In the
follow-up survey (ECRHS II) of the clinical stage 2 more
than 10,000 adults from 29 centres in 14 countries par-
ticipated (1998–2001). Detailed descriptions of the
methods for ECRHS I and ECRHS II have previously
been published [18, 19]. ECRHS III was the third wave
of data collection on the cohort, beginning in 2008.
Those who took part in the clinical stages of ECRHS I
and II were again contacted, with responders invited to a
local fieldwork centre, situated in an outpatient clinic or
lung function laboratory. Information was gathered from
standardised interviews by well-trained fieldworkers.
The current analyses were restricted to 3011 never
and former smoking adults from the random sample
who participated in all three surveys and had in-
formation on second-hand smoke exposure at all three
examinations.
Definition of smoking and second-hand smoke
At each survey participants were asked “Have you ever
smoked for as long as a year?”, and if yes, “Do you
smoke now as of one month ago?” Current smokers
answered both questions in the affirmative and were
excluded. Those who answered the lead question in the
negative were classified as never smokers, and ex-
smokers were those who answered they had smoked but
did not in the last month. Smokers and former smokers
were asked about duration of smoking and number of
cigarettes smoked per day and pack years were calcu-
lated. For analytical purposes smoking status was con-
sidered as categorical variables never smoker, ex-smoker
with less than 15 pack years and ex-smoker with at least
15 pack years.
Exposure to second-hand smoke was assessed by the
question “Have you been regularly exposed to tobacco
smoke in the last 12 months?”. Study participants an-
swering in the affirmative were classified as being ex-
posed to second-hand smoke.
Definition of respiratory health parameters
Information on the following respiratory symptoms and
diseases were collected: physician-diagnosed asthma,
chronic bronchitis and COPD, as well as on respiratory
symptoms such as wheeze, dyspnoea, cough and spu-
tum. The asthma related symptoms were combined in
an asthma score [20]. The following criteria for outcome
assessment were used:
 Physician-diagnosed asthma: “Have you ever had
asthma?” and “Was this confirmed by a doctor?”
were answered in the affirmative.
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 Asthma symptom score: The sum of positive
answers to the following five questions, i.e. the
asthma score ranges from 0 to 5, according to
Sunyer et al. [20]: 1) “Have you been breathless
while wheezing in the last 12 months?”; 2) “Have
you been woken up with a feeling of chest tightness
in the last 12 months?”; 3) “Have you had an attack
of shortness of breath whilst at rest in the last 12
months?”; 4) “Have you had an attack of shortness
of breath after activity in the last 12 months?” and
5) “Have you been woken by an attack of shortness
of breath in the last 12 months?”
 Nocturnal dyspnoea: “Have you been woken by an
attack of shortness of breath at any time during the
last twelve months?” was answered in the
affirmative.
 Cough: positive answer to at least one of “Have you
been woken by an attack of coughing at any time in
the last twelve months?”, “Do you usually cough first
thing in the morning in the winter?” and “Do you
usually cough during the day or night in the winter?”
 Sputum: positive answer to at least one of the
following questions: “Do you usually bring up
phlegm from your chest first thing in the morning
in the winter?” and “Do you usually bring up any
phlegm from your chest during the day or at night
in the winter?”
 Chronic bronchitis: “Do you usually cough during
the day or night on most days for as much as three
months per year?” and “Do you usually bring up any
phlegm from your chest on most days for as much
as three months per year?” were answered in the
affirmative.
Lung function testing
Lung function testing was performed by spirometry dur-
ing the clinical examination according to the ATS/ERS
recommendations [21]. Lung function measures were
performed in a sitting position while the subjects were
wearing nose clips. At least five, but not more than nine,
forced expiratory manoeuvres were performed. The
maximum forced expiratory volume in 1 s (FEV1) and
maximum forced vital capacity (FVC) of the technically
acceptable manoeuvres were determined. Spirometric
lung function measurements pre-bronchodilation were
used in the current analyses. Different spirometers were
used across the study centres and follow-up time points
within study centres.
Standardised z-scores were calculated based on the
reference equations for spirometry from the Global Lung
function Initiative (GLI - https://www.ers-education.org/
guidelines/global-lung-function-initiative.aspx) [22].
The presence of COPD was based on lung function
testing. Study participants with a ratio of FEV1 and FVC
(measured pre-bronchodilation) below the lower limit of
normal (LLN) according to the reference equations for
spirometry from the Global Lung function Initiative [22]
were classified as COPD patients. It was also defined as the
ratio of FEV1 and FVC (measured pre-bronchodilation)
below 0.7.
Definition of confounders
Potential confounding variables were assessed by ques-
tionnaire or measured at the physical examination.
These included sex, age, maternal smoking during preg-
nancy and/or childhood, paternal smoking during child-
hood and occupational exposure to dust and fumes.
Smoking status was defined as never smoker, ex-smoker
with less than 15 pack years and ex-smoker with at least
15 pack years. Socioeconomic status was defined based
on the age when fulltime education was completed (less
than 17 years, 17 to 20 years and more than 20 years).
Allergen specific IgE was measured at baseline against
D. pteronyssinus, cat, timothy grass and Cladosporium
using the Pharmacia CAP System and allergic sensitisa-
tion was defined as being sensitised to any of these aller-
gens using a cut-off of 0.35 kUA/L.
Height and weight were measured without shoes and
in light clothes at the physical examination.
Statistical analyses
We modelled the longitudinal impact of changes of
second-hand smoke exposure on respiratory health out-
comes. The effect of change in second-hand smoke
exposure over two examinations on lung function pa-
rameters as well as respiratory symptoms and diseases at
follow-up was analysed separately for ECRHS I-II,
ECRHS II-III and ECRHS I-III. Therefore, study partici-
pants were categorised into four groups: those not ex-
posed to second-hand smoke at both examinations
(reference category); those not exposed to second-hand
smoke at the first examination, but at the second exam-
ination (SHS increase); those exposed to second-hand
smoke at the first examination, but not at the second
examination (SHS decrease) and those exposed to
second-hand smoke at both examinations (SHS both).
Mixed effects logistic regression models and negative
binomial mixed effects models with random intercept
for study centre were used for respiratory symptoms/
diseases and asthma symptom score, respectively. Linear
mixed effects models with random intercept for study
centre were used to assess the association of change in
second-hand smoke exposure and lung function parame-
ters. All models were adjusted for sex, age, weight,
maternal and paternal smoking, exposure to dust/fumes,
allergic sensitisation, smoking status and socioeconomic
status assessed at baseline and additionally for baseline re-
spiratory symptom/disease and lung function, respectively.
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The models for the association between change in
second-hand smoke exposure and lung function were
additionally adjusted for height, weight squared and age
squared (to model the non-linear relationship of weight
and age with lung function). All continuous covariates
were standardised (with mean 0 and variance 1).
The associations between exposure to second-hand
smoke at baseline and lung function parameters at the
three surveys were analysed to evaluate the effect of
second-hand smoke exposure on lung function over
time. Therefore, linear mixed effects models were fitted
with random intercept for study participants nested in
the study centre, and an interaction term between
second-hand smoke exposure and time of follow-up, i.e.
the time between the particular examinations, was in-
cluded to model the impact of second-hand smoke ex-
posure on lung function decline [23].
Interaction terms with sex, maternal smoking and pater-
nal smoking were tested. Results from stratified analyses
are therefore reported. In addition, sensitivity analyses re-
stricted to never smokers at all three surveys (n = 1974
lifetime never smokers) were performed. For the associ-
ation between change in second-hand smoke exposure
over time and lung function at follow-up, additional ana-
lyses using percent predicted values according to the
Global Lung function Initiative [22] were conducted.
The results for the association between second-hand
smoke exposure with respiratory symptoms and diseases
are presented as odds ratio (OR) with corresponding
95% confidence interval (CI), whereas the results for the
association of second-hand smoke exposure with lung
function parameters are presented as regression coeffi-
cients (β) with corresponding 95% CI. For the asthma
symptom score, the results are presented as count ratio
(CR) with corresponding 95% CI.
All analyses were performed using the statistical soft-
ware R, version 3.4.3 [24], and the R packages “lme4”
and “lmerTest”.
Results
Description of study population and temporal changes of
second-hand smoke exposure and lung function
The analyses were based on 3011 non-smoking adults
from 26 study centres who participated in all three sur-
veys and had information on second-hand smoke expos-
ure at all three examinations (Fig. 1). The prevalence of
reported exposure to second-hand smoke decreased in
all participating study centres from ECRHS I to III
(Table 1). Overall, at the first examination, 38.7% were
exposed to second-hand smoke, 23.0% at the second
examination and 7.1% at the third examination. The
prevalences were highest in Spain.
The prevalence of respiratory symptoms and diseases
and the distribution of lung function parameters and
confounding variables in each survey are summarised
in Table 2.
Table 3 shows the change in second-hand smoke ex-
posure from ECRHS I-II, ECRHS II-III as well as ECRHS
I-III. Almost 7% (ECRHS I-II) and 2.5% (ECRHS II-III)
of the study participants were not exposed at the first,
but were exposed at the second examination.
The distribution of the lung function parameters as well
as the annual decline are summarised in Table 4. All lung
function parameters (FEV1, FVC and FEV1/FVC) decreased
over time, with greater decline in the second 10 year fol-
low-up period (ECRHS II-III; 42ml/year decline in FEV1)
compared to the first 10 year period (ECRHS I-II; 24ml/
year decline in FEV1) as expected with ageing of the
population.
Adjusted associations between change in second-hand
smoke exposure over time and respiratory symptoms
and diseases at follow-up [ECRHS I-II, ECRHS II-III and
ECRHS I-III]
Adjusted time variant analysis of second-hand smoke ex-
posure showed that those reporting increased second-
hand smoke exposure had increased risks for the
development of doctor-diagnosed asthma, chronic bron-
chitis and increased asthma symptom score, reaching con-
ventional levels of significance from ECRHS II-III as well
as from ECRHS I-III overall (Fig. 2). However, compared
to those not exposed on both occasions there was no evi-
dence that those reporting exposure on both occasions
had an increased risk of asthma or chronic bronchitis.
However, asthma score did increase in this group com-
pared to the non-exposed. An increased risk of nocturnal
dyspnoea was observed only for those reporting increased
second-hand smoke exposure between the first and the
third survey but not for those exposed at both surveys.
Spirometrically defined COPD was not statistically sig-
nificantly associated with changes in second-hand smoke
exposure at any of the examined periods over the 20 years
after adjustment for several selected confounders (Fig. 2).
Adjusted associations between change in second-hand
smoke exposure over time and lung function parameters
at follow-up
There was no association of second-hand smoke expos-
ure with FEV1.
Study participants exposed to second-hand smoke at
the first as well as at the second survey (ECRHS I-II)
had a reduced forced vital capacity at the second survey
(approximately 50 ml) compared to those not exposed to
second-hand smoke at these two surveys (Fig. 3) – but
there was no clear or consistent pattern of association
over the entire study period.
Similarly the ratio of FEV1/FVC showed associations
with increased second-hand smoke exposure from
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ECRHS I-II but no consistent pattern when the data
were examined over the entire period.
Sensitivity analyses using percent predicted values ac-
cording to the Global Lung function Initiative showed
comparable results (Additional file 1: Table S1).
Adjusted associations between second-hand smoke
exposure at the first examination and lung function as
well as lung function decline
The associations of exposure to second-hand smoke at
the first examination (ECRHS I) with lung function as
well as lung function decline from ECRHS I-III are sum-
marised in Table 5. Exposure to second-hand smoke at
the first examination resulted in reduced FEV1 and FVC
over time, with stronger effects for males compared to fe-
males. It also shows that those exposed to second-hand
smoke at the first examination had a slightly slower
decline in lung function compared to those not exposed.
Sensitivity analyses restricted to lifetime never smo-
kers, i.e. participants who were never smokers at all
three surveys showed comparable results (data not
shown).
Fig. 1 Flow chart of study population
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Discussion
This study investigated the association of exposure to
second-hand smoke with respiratory symptoms and
diagnoses, as well as lung function and lung function de-
cline in never and former smoking participants in
ECRHS I-III. We show that the proportion of the stud-
ied population exposed to second-hand smoke fell mark-
edly over the follow-up period of 20 years. Individuals
who became exposed to second-hand smoke over time
were at increased risk of doctor-diagnosed asthma,
chronic bronchitis as well as a higher asthma symptom
score. Associations between increase in second-hand
smoke exposure and incidence of COPD or lung func-
tion were not apparent.
Comparison with results from other epidemiology studies
Only a few studies have examined the association of
exposure to second-hand smoke with onset of asthma in
adulthood. In the prospective U.S. Black Women’s
Health Study, Coogan et al. observed a positive associ-
ation of passive smoke exposure with the incidence of
adult-onset asthma over 15 years of follow-up in 46,182
women aged 21 to 69 years at baseline [25]. Non-smoking
study participants who were exposed to second-hand smoke
had a 21% increase (adjusted HR: 1.2; 95%-CI: 1.0–1.5) in
asthma incidence compared to those not exposed. Similar
findings were observed in two Finnish population-based
case-control studies [26, 27]. Exposure to second-hand
smoke at the workplace or at home increased the risk for
the development of asthma during a period of 2.5 years
[27]. In our study, an increase in second-hand smoke ex-
posure over time was associated with an increased risk of
doctor-diagnosed asthma. An increased asthma symptom
score was observed for those reporting increased
second-hand smoke exposure as well as for those exposed
on both occasions. A decrease in second-hand smoke
exposure was also associated with an increased asthma
symptom score. However, this association was not
Table 1 Number of participants and prevalence of second-hand smoke (SHS) exposure by study centre
n SHS exposure in ECRHS I, % SHS exposure in ECRHS II, % SHS exposure in ECRHS III, %
Antwerp South (Belgium) 104 48.1 (50/104) 32.7 (34/104) 7.7 (8/104)
Antwerp City (Belgium) 99 50.5 (50/99) 36.4 (36/99) 9.1 (9/99)
Hamburg (Germany) 110 46.4 (51/110) 26.4 (29/110) 10.0 (11/110)
Erfurt (Germany) 107 38.3 (41/107) 26.2 (28/107) 6.5 (7/107)
Barcelona (Spain) 54 64.8 (35/54) 40.7 (22/54) 14.8 (8/54)
Galdakao (Spain) 139 74.1 (103/139) 51.1 (71/139) 23.0 (32/139)
Albacete (Spain) 69 68.1 (47/69) 42.0 (29/69) 15.9 (11/69)
Oviedo (Spain) 50 56.0 (28/50) 52.0 (26/50) 28.0 (14/50)
Huelva (Spain) 43 58.1 (25/43) 53.5 (23/43) 18.6 (8/43)
Bordeaux (France) 63 50.8 (32/63) 28.6 (18/63) 6.3 (4/63)
Grenoble (France) 212 34.0 (72/212) 25.5 (54/212) 6.6 (14/212)
Montpellier (France) 88 34.1 (30/88) 13.6 (12/88) 1.1 (1/88)
Paris (France) 186 40.3 (75/186) 33.3 (62/186) 4.8 (9/186)
Pavia (Italy) 51 64.7 (33/51) 47.1 (24/51) 2.0 (1/51)
Turin (Italy) 39 51.3 (20/39) 38.5 (15/39) 12.8 (5/39)
Verona (Italy) 57 35.1 (20/57) 17.5 (10/57) 7.0 (4/57)
Ipswich (UK) 93 31.2 (29/93) 20.4 (19/93) 7.5 (7/93)
Norwich (UK) 88 36.4 (32/88) 11.4 (10/88) 3.4 (3/88)
Reykjavik (Iceland) 197 47.2 (93/197) 26.4 (52/197) 7.1 (14/197)
Bergen (Norway) 186 30.1 (56/186) 11.8 (22/186) 5.4 (10/186)
Gothenburg (Sweden) 149 46.3 (69/149) 6.7 (10/149) 2.7 (4/149)
Umea (Sweden) 162 22.2 (36/162) 8.6 (14/162) 4.9 (8/162)
Uppsala (Sweden) 216 18.1 (39/216) 3.7 (8/216) 1.4 (3/216)
Basel (Switzerland) 221 24.4 (54/221) 16.3 (36/221) 6.8 (15/221)
Melbourne (Australia) 165 13.3 (22/165) 8.5 (14/165) 1.8 (3/165)
Tartu (Estonia) 63 34.9 (22/63) 25.4 (16/63) 3.2 (2/63)
Overall 3011 38.7 (1164/3011) 23.0 (694/3011) 7.1 (215/3011)
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consistent, being only recorded from ECRHS I to ECRHS
II, and the strength of the association was rather low. Of
note, the ECRHS questionnaire had not been specifically
devised to assess changes in respiratory symptoms after
smoking cessation or decrease in second-hand smoke
exposure. Overall our study findings are consistent with
results of the few other studies on second-hand smoke
and asthma development in adults.
Previous studies have investigated the association of ex-
posure to second-hand smoke with respiratory symptoms
Table 2 Prevalence of respiratory symptoms and diseases and distribution of lung function parameters and confounding variablesa
ECRHS I ECRHS II ECRHS III
SHS exposed
(n = 1164)
SHS non-exposed
(n = 1847)
SHS exposed
(n = 694)
SHS non-exposed
(n = 2317)
SHS exposed
(n = 215)
SHS non-exposed
(n = 2796)
Sex, female 52.0 (605/1164) 55.5 (1025/1847) 51.9 (360/694) 54.8 (1270/2317) 58.6 (126/215) 53.8 (1504/2796)
Age, years 33.8 (7.5) 35.1 (6.9) 43.5 (7.3) 43.3 (7.1) 53.8 (6.9) 54.7 (7.2)
Age completed full time education
< 17 years 19.4 (212/1093) 13.8 (232/1686) 24.7 (160/649) 13.3 (284/2130) 29.6 (59/199) 14.9 (385/2580)
17–20 years 39.1 (427/1093) 33.6 (567/1686) 39.8 (258/649) 34.6 (736/2130) 39.7 (79/199) 35.5 (915/2580)
> 20 years 41.5 (454/1093) 52.6 (887/1686) 35.6 (231/649) 52.1 (1110/2130) 30.7 (61/199) 49.6 (1280/2580)
Height, cm 170.4 (9.8) 170.6 (9.5) 169.6 (10.0) 170.9 (9.5) 167.2 (10.2) 170.1 (9.7)
Weight, kg 70.2 (14.0) 68.7 (13.2) 74.5 (15.0) 73.6 (14.9) 77.7 (14.2) 77.6 (16.1)
Paternal smoking 63.3 (714/1128) 58.2 (1059/1819) 67.2 (452/673) 58.1 (1321/2274) 72.9 (153/210) 59.2 (1620/2737)
Maternal smoking 20.5 (237/1155) 20.3 (373/1834) 17.8 (123/690) 21.2 (487/2299) 18.2 (39/214) 20.6 (571/2775)
Allergic sensitisation,
IgE
26.5 (267/1007) 33.8 (538/1593) 26.0 (151/581) 32.4 (654/2019) 28.4 (50/176) 31.1 (755/2424)
Dust/fumes exposure 41.8 (484/1159) 35.7 (653/1828) 42.7 (296/694) 39.0 (904/2316) 38.5 (77/200) 22.1 (572/2583)
Ex-smoker 31.2 (363/1164) 28.7 (531/1847) 33.3 (231/694) 29.5 (684/2317) 31.6 (68/215) 29.0 (810/2796)
Smoking status
Never smoker 69.2 (801/1158) 71.4 (1316/1844) 67.9 (463/682) 73.0 (1633/2236) 70.0 (147/210) 73.3 (1986/2709)
Ex-smoker with < 15
pack-years
23.2 (269/1158) 22.3 (412/1844) 21.6 (147/682) 21.2 (474/2236) 16.2 (34/210) 20.1 (544/2709)
Ex-smoker with > = 15
pack-years
7.6 (88/1158) 6.3 (116/1844) 10.6 (72/682) 5.8 (129/2236) 13.8 (29/210) 6.6 (179/2709)
Asthma, doctor-
diagnosed
7.1 (82/1160) 7.4 (136/1846) 10.4 (72/694) 10.8 (250/2312) 15.0 (32/213) 13.8 (385/2792)
Chronic bronchitis 1.4 (16/1162) 1.3 (24/1846) 2.3 (16/693) 1.2 (27/2314) 4.2 (9/215) 2.1 (59/2789)
COPD, FEV1/FVC < 0.7 2.7 (29/1078) 3.4 (59/1731) 2.5 (16/630) 4.4 (89/2042) 9.3 (18/193) 10.8 (264/2448)
COPD, FEV1/FVC <
GLI LLN
4.6 (50/1077) 4.5 (78/1731) 2.2 (14/629) 3.8 (77/2038) 5.7 (11/193) 5.8 (142/2445)
Asthma symptom score
0 74.8 (866/1157) 76.0 (1392/1831) 67.9 (468/689) 75.0 (1723/2298) 65.6 (137/209) 72.7 (1974/2714)
1 14.1 (163/1157) 13.0 (238/1831) 18.3 (126/689) 13.6 (313/2298) 16.7 (35/209) 16.8 (455/2714)
2 5.7 (66/1157) 5.4 (99/1831) 6.7 (46/689) 5.9 (136/2298) 7.7 (16/209) 6.0 (163/2714)
3 2.9 (33/1157) 2.8 (51/1831) 3.5 (24/689) 3.1 (72/2298) 4.8 (10/209) 2.5 (67/2714)
4 1.6 (18/1157) 1.6 (30/1831) 2.5 (17/689) 1.6 (36/2298) 3.3 (7/209) 1.0 (26/2714)
5 1.0 (11/1157) 1.1 (21/1831) 1.2 (8/689) 0.8 (18/2298) 1.9 (4/209) 1.1 (29/2714)
Dyspnoea 4.6 (54/1163) 4.9 (90/1847) 6.5 (45/694) 5.2 (120/2310) 9.0 (19/211) 5.2 (142/2743)
Cough 33.6 (390/1159) 29.7 (547/1842) 35.3 (244/692) 31.7 (733/2312) 40.1 (85/212) 33.7 (936/2778)
Sputum 11.2 (129/1153) 10.1 (185/1827) 12.0 (83/692) 10.0 (230/2298) 15.2 (32/211) 10.9 (302/2769)
FEV1, ml 3800 (824) 3781 (835) 3522 (805) 3595 (819) 3028 (756) 3123 (778)
FVC, ml 4573 (1032) 4591 (1058) 4306 (1000) 4458(1030) 3904 (995) 4063 (993)
FEV1/FVC, % 83.5 (6.7) 82.8 (6.5) 82.1 (5.9) 80.9 (6.1) 77.6 (5.6) 77.0 (5.7)
astratified by exposure to second-hand smoke (SHS) and presented as % (n/N) for categorical variables and mean (SD) for continuous variables, respectively
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and diseases, especially COPD. For instance, Eisner et al.
[6] analysed the effect of lifetime exposure to second-hand
smoke on the risk for the development of COPD in 2112
adults (including current, former and never smokers) aged
55 to 75 years in the U.S. It showed a positive significant
association between cumulative exposure to second-hand
smoke at home (adjusted OR: 1.6; 95%-CI: 1.1–2.2) as well
as at work (adjusted OR: 1.4; 95%-CI: 1.0–1.8) with
self-reported doctor-diagnosed COPD. A Chinese study
[8] also investigated the relationship of self-reported
density and duration of exposure to passive smoking with
respiratory symptoms (cough, phlegm and shortness of
breath) and COPD (FEV1/FVC < 0.7 measured pre-bron-
chodilation) based on data from 15,379 never smoking
adults in the Guangzhou Biobank Cohort Study. Exposure
to second-hand smoke at home and at work was signifi-
cantly associated with an increased risk of COPD (ad-
justed OR: 1.5; 95%-CI: 1.2–1.9) and any respiratory
symptoms (adjusted OR: 1.2; 95%-CI: 1.1–1.3).
An increased risk of COPD, defined using the fixed ra-
tio of FEV1/FVC < 0.7 measured post-bronchodilation,
was seen in those with second-hand smoke exposure in
a study [28] of 2182 lifelong never smokers taking part
in the Obstructive Lung Disease in Northern Sweden
(OLIN) studies. Exposure to second-hand smoke was
categorised into several groups based on previous and
current exposure to second-hand smoke at home and at
work. The strongest associations were seen in those ever
exposed at home and at both previous and current work
(adjusted OR: 3.8; 95%-CI: 1.3–11.2) as well as for those
currently exposed at home and at both previous and
current work (adjusted OR: 5.7; 95%-CI: 1.5–22.5). A
significant dose dependent relationship of exposure to
second-hand smoke with mortality from different dis-
eases, including COPD amongst other causes of death,
could be shown in another study [10]. In contrast, a
study conducted by Chan-Yeung et al. [9] found no
association between exposure to second-hand smoke
and an increased risk for COPD in a small sex- and
age-matched case-control study comprising 289 patients
and controls, respectively, in Hong Kong, China.
The different associations between exposure to
second-hand smoke and COPD in the above studies might
be due to the different definition of COPD as some studies
used questionnaire-based information whereas others
used spirometric measurements. Furthermore, some stud-
ies were restricted to lifetime never smokers compared to
studies also including active smokers. We have shown no
significant association between increase in second-hand
smoke exposure and incidence of COPD based on lung
function testing in our study, which was restricted to
never and former smokers. The different observed associ-
ations might also be due to residual confounding in some
studies or potential misclassification of self-reported ex-
posure to second-hand smoke in our study.
Another study, based on Taiwan’s National Health In-
surance Bureau claims data, investigated the association
of exposure to second-hand smoke and chronic bronchitis
in women [29] and showed that women who were ex-
posed to second-hand smoke had a 3.7 (95%-CI: 1.2–11.3)
higher risk of chronic bronchitis compared to those not
exposed to second-hand smoke. Furthermore, exposure to
second-hand smoke was also associated with mild
(adjusted OR: 1.8; 95%-CI: 1.1–2.9) and moderate (adjusted
OR: 3.8; 95%-CI: 1.7–8.6) COPD as defined by GOLD.
We have shown a significant positive association of
new exposure to second-hand smoke between two sur-
veys with chronic bronchitis at follow-up, defined as
having cough and sputum. However there was no evi-
dence of a decrease in chronic bronchitis if exposure to
second-hand smoke stopped over the same time frame.
In addition, exposure to second-hand smoke was not
Table 3 Second-hand smoke (SHS) exposure in ECRHS I-II, ECRHS II-III and ECRHS I-IIIa
Changes between ECRHS I and II Changes between ECRHS II and III Changes between ECRHS I and III
No SHS exposure at both examinations 54.4 (1639/3011) 74.5 (2243/3011) 58.9 (1774/3011)
No SHS exposure at first examination but
at second examination
6.9 (208/3011) 2.5 (74/3011) 2.4 (73/3011)
SHS exposure at first examination but not
at second examination
22.5 (678/3011) 18.4 (553/3011) 33.9 (1022/3011)
SHS exposure at both examinations 16.1 (486/3011) 4.7 (141/3011) 4.7 (142/3011)
apresented as % (n/N)
Table 4 Distribution of lung function parameters and annual changea
ECRHS I ECRHS II ECRHS III Difference between ECRHS I
and II (ml or % per year)
Difference between ECRHS II
and III (ml or % per year)
Difference between ECRHS I
and III (ml or % per year)
FEV1 (ml) 3789 (830) 3578 (816) 3116 (777) −24 (36) −42 (26) −34 (17)
FVC (ml) 4584 (1048) 4422 (1025) 4052 (994) −19 (45) −34 (35) −27 (21)
FEV1/FVC (%) 83 (7) 81 (6) 77 (6) −0.2 (0.5) −0.4 (0.4) − 0.3 (0.3)
apresented as mean (SD)
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associated with COPD defined by a ratio of FEV1/FVC
below 0.7 [30, 31]. According to the original classifica-
tion of COPD from the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) in 2001 [32], stage 0
“at risk” is characterised by chronic symptoms (sputum
production and cough) with still normal spirometry, i.e.
the ratio between FEV1 and FVC of at least 0.7. This
GOLD stage 0 would be similar to the definition of
chronic bronchitis used in this analysis which requires a
positive answer to both the question on cough and the
question on sputum, independent of lung function.
Moreover, the overlap between chronic bronchitis and
COPD defined by spirometry was quite small in this
study. As an effect of exposure to second-hand smoke
was found in this study only for chronic bronchitis, but
not for COPD, one might speculate that these results
Fig. 2 Associations between change in second-hand smoke (SHS) exposure over time and respiratory symptoms/diseases at follow-up. SHS
never: no SHS exposure at both examinations (reference category); SHS increase: no SHS exposure at first examination but at second examination;
SHS decrease: SHS exposure at first examination but not at second examination; SHS both: SHS exposure at both examinations. All models are
adjusted for sex, age, weight, maternal smoking, paternal smoking, combination of smoking status and pack years, education, exposure to dust/
fumes, allergic sensitisation (at baseline) and baseline respiratory symptom/disease
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indicate a transient effect, but not structural changes in
the airways as would be common in COPD patients.
Although COPD is generally considered a disease
characterised by a progressive, gradually accelerating de-
cline in FEV1 Macklem has pointed out that increase in
residual volume (RV) is the first functional abnormality
in chronic bronchitis [33]. Thus, gas trapping with re-
duction of FVC is an early abnormality because RV in-
creases more than the total lung capacity (TLC). The
observed decrease in FEV1 occurs because of a reduction
Fig. 3 Associations between change in second-hand smoke (SHS) exposure over time and lung function at follow-up. SHS never: no SHS exposure at
both examinations (reference category); SHS increase: no SHS exposure at first examination but at second examination; SHS decrease: SHS exposure at
first examination but not at second examination; SHS both: SHS exposure at both examinations. All models are adjusted for sex, age, age squared,
weight, weight squared, height, maternal smoking, paternal smoking, combination of smoking status and pack years, education, exposure to dust/
fumes, allergic sensitisation (at baseline) and baseline lung function
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in FVC. The FEV1/FVC ratio will decrease because of loss
of lung elastic recoil, a sine qua non of COPD [33, 34] but
early in the disease the decrease in FVC may exceed that
in FEV1 with a paradoxical effect on the FEV1/FVC ratio.
This may explain why we did not see an association with
COPD defined by spirometric lung function parameters.
A reduced FEV1 and FVC over time was observed for
those reporting exposure to second-hand smoke at the
first examination, with stronger effects for males com-
pared to females. Several studies have investigated the
association between second-hand smoke exposure and
lung function, suggesting sex differences in vulnerability
[35–38]. However, the findings are inconsistent. Some
studies found adverse effects of passive smoking on spiro-
metric lung function parameters for both sexes [35, 38],
whereas another study found stronger effects for women
compared to men [36]. Our results are consistent with find-
ings of the study conducted by Masjedi et al. [37] showing
a negative association between second-hand smoke expos-
ure and lung function among men, but not among women.
Janson et al. [39] investigated changes and determi-
nants for changes in active as well as passive smoking in
the first and second survey of the European Community
Respiratory Health Survey showing that exposure to
second-hand smoke was higher among subjects with
lower socio-economic status and educational level. Fur-
thermore, subjects exposed to second-hand smoke were
less likely to quit smoking suggesting that a decrease in
second-hand smoke exposure might be effective in
decreasing active smoking. In our study, exposure to
second-hand smoke decreased during the 20 years of
follow-up where for many of the study centres the de-
crease between the second 10 year follow-up period was
stronger compared to the first 10 year period. However,
second-hand smoke exposure was still present in all par-
ticipating centres.
Strengths and limitations
The European Community Respiratory Health Survey
has a longitudinal study design with two follow-ups ap-
proximately 10 and 20 years, respectively, after the first
survey and therefore we can model the association be-
tween changes in second-hand smoke exposure over
time with respiratory health outcomes. We are also able
to investigate the effect of exposure to second-hand
smoke at baseline on lung function decline using spiro-
metric measurements that were performed and quality
controlled according to well established guidelines. Also
the large study population of around 2000 never-smoking
study participants and the high number of participating
centres and countries are further strengths.
However this study has some limitations. The informa-
tion on second-hand smoke exposure as well as res-
piratory symptoms and diseases was obtained using
self-administered questionnaires completed at follow-up
and no biomarkers for exposure to second-hand smoke
were available. Moreover, the information on second-hand
some exposure was only requested for the last 12months
at each survey and not for the total study period. Further-
more, information on the number of cigarettes smoked by
other people was not available. No dose-related associ-
ation between second-hand smoke exposure and respira-
tory health has been investigated which has to be taken
into account when drawing conclusions.
In addition, against a backdrop of falling smoking rates
and smoke free legislation across Europe only a small
Table 5 Associations between second-hand smoke (SHS) exposure at the first examination and lung function and decline
Total Male Female
β 95%-CI p-value β 95%-CI p-value β 95%-CI p-value
FEV1
a
SHS exposureb −44 (−82, −5) 0.03 −75 (− 140, − 11) 0.02 −13 (− 57, 31) 0.56
SHS exposure*follow-up timec 1 (0, 3) 0.03 2 (0, 4) 0.03 1 (−1, 3) 0.19
FVCa
SHS exposureb − 56 (−102, − 10) 0.02 − 102 (− 179, − 24) 0.01 −19 (−71, 33) 0.47
SHS exposure*follow-up timec 2 (0, 4) 0.02 3 (0, 6) 0.03 2 (0, 4) 0.09
FEV1/FVC
a
SHS exposureb 0.0 (− 0.5, 0.5) 0.96 0.1 (− 0.6, 0.9) 0.71 0.1 (−0.6, 0.7) 0.88
SHS exposure*follow-up timec 0.0 (0.0, 0.0) 0.94 0.0 (0.0, 0.0) 0.96 0.0 (0.0, 0.0) 0.62
Models are adjusted for age, age squared, weight, weight squared, height, combination of smoking status and pack years, maternal smoking, paternal smoking,
allergic sensitisation, education and exposure to dust/fumes as well as for sex in the total study population
aan interaction term between time between follow-ups and SHS exposure is included to determine the effect of SHS exposure on lung function decline
ba negative estimate suggests that those exposed to SHS at the first examination had lower average lung function at all three examinations than those
not exposed
ca negative estimate suggests that those exposed to SHS at the first examination had a higher decline in lung function between the examinations than those
not exposed
* indicating the interaction term between SHS exposure and time of follow-up
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proportion of the study group became newly exposed to
second-hand smoke over the period of the study.
Questionnaire-based information on second-hand smoke
exposure might be prone to reporting bias as subjects
having respiratory symptoms or diseases might tend to
be more affected. Siroux et al. [40] has found no indica-
tion that asthma status influences reporting of exposure
to second-hand smoke in childhood or adulthood but
we cannot exclude that our results are related to report-
ing biases. The use of different spirometers across study
centres and surveys could have resulted in temporal dif-
ferences in lung function measurements. Sensitivity
analyses using lung function values corrected for this
change showed comparable results. Furthermore, it was
difficult to disentangle the survey and age effects due to
three time points comprising two follow-ups each after
approximately 10 years as different findings were observed
for the association of new exposure to second-hand smoke
between two surveys with respiratory symptoms and dis-
eases at follow-up.
The questions on cough and sputum were only re-
quested for winter and not for summer, as these symp-
toms are often more worse during the winter months.
Furthermore, no information on the change of the venti-
lation equipment used for air cleaning during the
follow-up periods was available and thus could not be
considered as potential confounding variable.
Conclusion
In a longitudinal analysis of adults, following a multi-centre
cohort over twenty years, exposure to second-hand smoke
decreased substantially during the study period. Second-
hand smoke exposure in adults was associated with an
increased risk for asthma and chronic bronchitis. Our
results support further restrictions on smoking in
public places.
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Additional file 1: Table S1. Associations between change in second-hand
smoke (SHS) exposure over time and lung function at follow-up [percent
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